BioCentury
ARTICLE | Product Development

Roche broadens its BD scope

James Sabry on what Spark deal says about Roche’s future BD strategy

March 2, 2019 1:10 AM UTC

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on indications and modalities.

On Feb. 25, Roche announced it would acquire Spark for $4.8 billion in cash...

BCIQ Company Profiles

Roche

Spark Therapeutics Inc.